Stay updated on Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.

Latest updates to the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page
- Check6 days agoChange DetectedAdded a government funding notice and a site revision (v3.4.1); removed the prior revision (v3.4.0); core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check13 days agoChange DetectedAdministrative updates to page metadata and UI elements, including adding a glossary display, and updating revision/version indicators while removing outdated metadata terms. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedFooter now shows Revision: v3.3.4, replacing v3.3.3. No study data or key information were modified.SummaryDifference0.1%

- Check34 days agoChange DetectedThe study status updated to Completed with actual completion dates (Primary Completion and Study Completion on 2025-12-15); the previous 'Active, not recruiting' status was removed.SummaryDifference0.5%

- Check48 days agoChange DetectedLocations section on the page was reorganized to list New Jersey, New York, and Pennsylvania as separate subsections, replacing the prior 'New Jersey Locations', 'New York Locations', and 'Pennsylvania Locations' headings. The HHS Vulnerability Disclosure link was removed from the footer and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.5%

- Check69 days agoChange DetectedAdded an Outcome Measure: Number of Adverse Events and a new Last Update Posted (Estimated) field; removed the Incidence of adverse events and Last Update Posted fields.SummaryDifference0.4%

Stay in the know with updates to Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.